AstraZeneca's Nexium Patent Remains Valid

Law360, New York (November 19, 2007, 12:00 AM EST) -- The European Patent Office has reportedly ruled that a patent covering AstraZeneca Plc's blockbuster heartburn drug Nexium is still valid in its amended form despite challenges from four generic competitors.

AstraZeneca said Monday that its patent, which covers a proton pump inhibitor used in drugs like Nexium and Losec, will now be valid in Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, the United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Portugal, Sweden, Latvia, Lithuania and Slovenia until 2015.

“AstraZeneca has a comprehensive intellectual property...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.